Trader consensus prices "No" at 84% for a new WHO-designated COVID variant of concern before 2027, driven by the absence of any recent SARS-CoV-2 strain meeting strict VOC criteria like significantly higher transmissibility, severity, or vaccine evasion. The emerging BA.3.2 "Cicada" subvariant, spreading across 30+ U.S. states and Europe since late March 2026, shows immune escape potential but no evidence of increased hospitalizations or deaths, per CDC and ECDC updates through April 24. Broad population immunity from updated 2025-2026 vaccines and prior infections, combined with Omicron's dominance as an endemic baseline, underpins this positioning, though global surveillance continues amid summer case upticks.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$237,606 Vol.
$237,606 Vol.
$237,606 Vol.
$237,606 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Market Opened: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Trader consensus prices "No" at 84% for a new WHO-designated COVID variant of concern before 2027, driven by the absence of any recent SARS-CoV-2 strain meeting strict VOC criteria like significantly higher transmissibility, severity, or vaccine evasion. The emerging BA.3.2 "Cicada" subvariant, spreading across 30+ U.S. states and Europe since late March 2026, shows immune escape potential but no evidence of increased hospitalizations or deaths, per CDC and ECDC updates through April 24. Broad population immunity from updated 2025-2026 vaccines and prior infections, combined with Omicron's dominance as an endemic baseline, underpins this positioning, though global surveillance continues amid summer case upticks.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions